Overview

OTR Tablet 40 mg Fasted-state Bioequivalence Study

Status:
Completed
Trial end date:
2018-03-20
Target enrollment:
Participant gender:
Summary
This is an open-label, single dose, randomised, cross-over study to confirm the bioequivalence (BE) of OTR tablet 40 mg and OXYCONTIN tablet 40 mg in a fasted state in Chinese subjects with chronic pain
Phase:
Phase 1
Details
Lead Sponsor:
Mundipharma (China) Pharmaceutical Co. Ltd
Treatments:
Oxycodone